Skip to main content
SpringerLink
Log in

Livedovaskulopathie

Pathogenese, Diagnostik und Therapie des Hautinfarkts

Livedoid vasculopathy

Pathogenesis, diagnosis and treatment of cutaneous infarction

  • CME Weiterbildung · Zertifizierte Fortbildung
  • Published:
Der Hautarzt Aims and scope Submit manuscript

Zusammenfassung

Die Livedovaskulopathie ist eine chronisch rezidivierende Erkrankung der kutanen Gefäßversorgung und gekennzeichnet durch das episodische Auftreten von schmerzhaften Ulzerationen der unteren Extremität. Diese heilen mit der Zeit unter der Ausbildung von kleinen Narben, der charakteristischen Atrophie blanche, ab. Es ist ein wichtiges Ergebnis von Forschungsbemühungen der letzten Jahre, dass die Livedovaskulopathie als Gerinnungsleiden von den primär entzündlichen Vaskulitiden abgegrenzt worden ist. Diese Differenzierung trägt zum besseren pathophysiologischen Verständnis bei und stützt zudem die therapeutischen Überlegungen. Die Verhinderung irreversibler narbiger Residuen ist das Hauptziel der Therapie des Hautinfarktes und erfordert entschlossenes Vorgehen.

Abstract

Livedo vasculopathy is a chronic recurrent disease of the cutaneous circulation and is characterized by episodic occurrence of painful ulcerations of the lower leg. These heal slowly leaving small porcelain-white scars called atrophie blanche. Recent research has shown that livedoid vasculopathy is a coagulation disorder classified as a vasculopathy different from inflammatory vasculitis. Distinguishing between the disorders enhances the pathophysiologic understanding and supports the therapeutic rationale. The prevention of irreversible residual scarring is the main goal in treating cutaneous infarction; prompt treatment is required.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2
Abb. 3
Abb. 4

Literatur

  1. Amital H, Levy Y, Shoenfeld Y (2000) Use of intravenous immunoglobulin in livedo vasculitis. Clin Exp Rheumatol 18:404–406

    PubMed  CAS  Google Scholar 

  2. Bard JW, Winkelmann RK (1967) Livedo vasculitis. Segmental hyalinizing vasculitis of the dermis. Arch Dermatol 96:489–499

    Article  PubMed  CAS  Google Scholar 

  3. Browning CE, Callen JP (2006) Warfarin therapy for livedoid vasculopathy associated with cryofibrinogenemia and hyperhomocysteinemia. Arch Dermatol 142:75–78

    Article  PubMed  Google Scholar 

  4. Callen JP (2006) Livedoid vasculopathy: What it is and how the patient should be evaluated and treated. Arch Dermatol 142:1481–1482

    Article  PubMed  Google Scholar 

  5. Deng A, Gocke CD, Hess J et al (2006) Livedoid vasculopathy associated with plasminogen activator inhibitor-1 promoter homozygosity (4G/4G) treated successfully with tissue plasminogen activator. Arch Dermatol 142:1466–1469

    Article  PubMed  Google Scholar 

  6. Dodman B, Cunliffe WJ, Roberts BE (1973) Observations on tissue fibrinolytic activity in patients with cutaneous vasculitis. Br J Dermatol 88:231–235

    Article  PubMed  CAS  Google Scholar 

  7. Emerging Risk Factors Collaboration, Danesh J, Erqou S, Kaptoge S et al (2009) Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA 302:412–423

    Article  Google Scholar 

  8. Feldaker M, Hines EA Jr, Kierland RR (1955) Livedo reticularis with summer ulcerations. AMA Arch Derm 72:31–42

    PubMed  CAS  Google Scholar 

  9. Fritsch P, Zelger B (1995) Livedo vasculitis. Hautarzt 46:215–224

    Article  PubMed  CAS  Google Scholar 

  10. Goerge T (2010) Niedermolekulare Heparin-Therapie zur Behandlung der Livedovaskulopathie. Aktuelle Derm 36:484–487

    Article  Google Scholar 

  11. Goerge T, Weishaupt C, Metze D et al (2010) Livedoid vasculopathy in a pediatric patient with elevated lipoprotein(a) levels: prompt response to continuous low-molecular-weight heparin. Arch Dermatol 146:927–928

    Article  PubMed  Google Scholar 

  12. Gray HR, Graham JH, Johnson W et al (1966) Atrophie blanche: periodic painful ulcers of lower extremities. A clinical and histopathological entity. Arch Dermatol 93:187–193

    Article  PubMed  CAS  Google Scholar 

  13. Hairston BR, Davis MD, Gibson LE et al (2003) Treatment of livedoid vasculopathy with low-molecular-weight heparin: report of 2 cases. Arch Dermatol 139:987–990

    Article  PubMed  Google Scholar 

  14. Jorizzo JL (1998) Livedoid vasculopathy: What is it? Arch Dermatol 134:491–493

    Article  PubMed  CAS  Google Scholar 

  15. Kreuter A, Gambichler T, Breuckmann F et al (2004) Pulsed intravenous immunoglobulin therapy in livedoid vasculitis: an open trial evaluating 9 consecutive patients. J Am Acad Dermatol 51:574–579

    Article  PubMed  Google Scholar 

  16. Meiss F, Marsch WC, Fischer M (2006) Livedoid vasculopathy. The role of hyperhomocysteinemia and its simple therapeutic consequences. Eur J Dermatol 16:159–162

    PubMed  Google Scholar 

  17. Metz J, Sturm G (1974) Atrophie blanche (so-called capillaritis alba). Hautarzt 25:105–109

    PubMed  CAS  Google Scholar 

  18. Meyer V, Schneider SW, Gorge T (2010) Dermatologic aspects of anticoagulation. Hautarzt 61:705–716; quiz 717–708

    Article  PubMed  CAS  Google Scholar 

  19. Papi M, Didona B, De Pita O et al (1998) Livedo vasculopathy vs small vessel cutaneous vasculitis: cytokine and platelet P-selectin studies. Arch Dermatol 134:447–452

    Article  PubMed  CAS  Google Scholar 

  20. Schobess R, During C, Bidlingmaier C et al (2006) Long-term safety and efficacy data on childhood venous thrombosis treated with a low molecular weight heparin: an open-label pilot study of once-daily versus twice-daily enoxaparin administration. Haematologica 91:1701–1704

    PubMed  CAS  Google Scholar 

  21. Sunderkotter C, De Groot K (2008) Therapie von Vaskulitiden und Vaskulopathien. Hautarzt 59:382–393

    Article  PubMed  CAS  Google Scholar 

Download references

Interessenkonflikt

Der korrespondierende Autor gibt an, dass kein Interessenkonflikt besteht.

Danksagung

Der Autor dankt Herrn Prof. Dr. C. Sunderkötter für die kritische Diskussion des Manuskripts und Prof. Dr. D. Metze und Dr. V. Dimitrova für die histologische Expertise.

Author information

Authors and Affiliations

  1. Hautklinik, Universitätsklinikum Münster, von Esmarchstr. 58, 48149, Münster, Deutschland

    T. Goerge

Authors
  1. T. Goerge
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to T. Goerge.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Goerge, T. Livedovaskulopathie. Hautarzt 62, 627–636 (2011). https://doi.org/10.1007/s00105-011-2172-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00105-011-2172-3

Schlüsselwörter

Keywords

Search

Navigation